Company news
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) news
Paradigm Biopharmaceuticals Ltd. news releases on 6ix. Latest, Sep 27, 2021: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION
Press releases — page 3
PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION
September 26, 2021
AUS ETHICS APPROVAL RECEIVED FOR PHASE 3 TRIAL
September 23, 2021
2021 Annual Report and Appendix 4E
August 26, 2021
PARADIGM REPORTS IND APPLICATION UPDATE
August 2, 2021
PARADIGM SUBMITS RESPONSES TO US FDA QUESTIONS
June 29, 2021
PARADIGM RECEIVES KEY REGULATORY APPROVALS FOR MPS VI STUDY
June 17, 2021
IND QUESTIONS RECEIVED FROM US FDA
May 24, 2021
PARADIGM ACHIEVES FIRST REVENUE
May 18, 2021
PARADIGM PROVIDES IND APPLICATION UPDATE
April 25, 2021
Paradigm doses first participant in Synovial Fluid Trial
April 13, 2021
Paradigm and Bene Execute New Collaboration Agreement
March 30, 2021
Paradigm delivers IND to US FDA for Pivotal OA Program
March 25, 2021
Consistent pain reduction and improvement in function data
February 2, 2021
Response to ASX Query
January 21, 2021
R&D Investor Presentation
December 20, 2020
PARADIGM RECEIVES POSTIVE FEEDBACK FROM FDA TYPE C MEETING
December 17, 2020
Paradigm Provides Phase 3 Clinical Trial Update
December 13, 2020
FIRST PATIENT DOSED IN MPS-I PHASE 2 CLINICAL TRIAL
November 11, 2020
ZILOSUL REDUCES PAIN IN PATIENTS WITH KNEE OA
September 30, 2020
EXTENSION OF EXCLUSIVE AGREEMENT WITH BENE PHARMACHEM
September 28, 2020
EMA PROVIDES KEY PATH TOWARD PHASE 3 TRIALS AND REGISTRATION
September 27, 2020
Paradigm Presentation to Emerging Leaders Conference
September 16, 2020
Appendix 4E and 2020 Annual Report
August 27, 2020
MPS RECEIVES CRITICAL APPROVALS AND FEEDBACK FROM AGENCIES
August 10, 2020
Quarterly Activities Report
July 31, 2020
EAP - 65% PAIN REDUCTION IN 10 OA PATIENTS IN USA
July 29, 2020
NEW FINANCIAL YEAR UPDATE
July 15, 2020
S&P DJI Announces June 2020 Quarterly Rebalance
June 11, 2020
BLOCK TRADE TO INSTITUTIONAL INVESTORS
May 12, 2020
EAP treatment completed and Orphan Status achieved for MPS-I
April 30, 2020
Reinstatement to Official Quotation
April 8, 2020
Paradigm completes $35m raising
April 7, 2020
Paradigm Reports Very Encouraging Real World Data
April 6, 2020
Paradigm receives clarity on US regulatory pathway
April 5, 2020
All 10 participants in US FDA EAP have commenced treatment
March 23, 2020
Paradigm reports Positive Pre-IND meeting with US FDA
February 20, 2020
Paradigm - first patient dosed in USA under FDA approved EAP
February 17, 2020
Paradigm presents MPS VI poster at WORLD Symposium
February 12, 2020
Cleansing Notice and Appendix 3B
December 18, 2019
Paradigm End of Calendar Year Update
December 11, 2019
Paradigm AGM Presentation
November 7, 2019
PARADIGM PROVIDES REGULATORY FILING UPDATE
October 24, 2019
Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
September 29, 2019
PAR Expanded Access IND Cleared by US FDA
September 10, 2019
Appendix 4E and 2019 Annual Report
August 30, 2019
PARs drug reduces cartilage degradation in subjects with OA
August 28, 2019
PARADIGM FILES FIRST IND WITH US FDA
August 6, 2019
Appendix 4C - quarterly
July 31, 2019
Paradigm EOFY Update
June 28, 2019
PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL
June 3, 2019